MYC amplification and overexpression is known to play a vital role in maintaining the malignancy of Group 3 MB; however, an incomplete understanding of how MYC drives tumorigenesis in a subset of Group 3 tumor cells has hampered the development of novel therapeutic approaches for this lethal disease. This evidence concerns the gene MYC and neoplasm.